Stock Groups

BioNTech CEO says can adapt vaccine quickly for Omicron -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This is a general view of BioNTech’s building, from which the production of COVID-19 vaccine (coronavirus disease) has been started in Marburg Germany. It was taken November 18, 2021. REUTERS/Fabian Bimmer

FRANKFURT(Reuters) – BioNTech, a German pharmaceutical company, said that it should be able quickly adapt its coronavirus vaccination to Omicron variants. Ugur Sahin from BioNTech was speaking at the Reuters Next conference.

Sahin said, “Vaccines should still provide protection against severe illness, regardless of mutations in virus.”

To watch the Reuters Next conference please register here https://reutersevents.com/events/next

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, futures, indexes or Forex. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. Because prices might not reflect the market, they may be incorrect. This means that prices cannot be considered indicative and are inappropriate for trading. Fusion Media does not accept any liability for trade losses caused by the data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]